Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines

European Journal of Cancer

Volumn 39, Issue 9, 2003, Pages 1318-1329

  Tomek, S ^c   Koestler, W ^a   Horak, P ^a   Grunt, T ^a   Brodowicz, T ^a   Pribill, I ^a   Halaschek, J ^a   Haller, G ^a   Wiltschke, C ^a   Zielinski, C C ^a,b   Krainer, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c NONE

Author keywords

Apoptosis; Caspase 8; Doxorubicin; FLIP; Paclitaxel; Soft tissue sarcoma; TRAIL

Indexed keywords

CASPASE 8; CYTOTOXIC AGENT; DOXORUBICIN; FLICE INHIBITORY PROTEIN; OSTEOPROTEGERIN; PACLITAXEL; RECEPTOR; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHONDROSARCOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; FIBROSARCOMA; HUMAN; HUMAN CELL; LIPOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

EID: 0037565276     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00227-2     Document Type: Article

References (55)

1. Antman K., Crowley J., Balcerzak S.P.et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 11:1993;1276-1285.
2. Borden E.C., Amato D.A., Edmonson J.H., Ritch P.S., Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer. 66:1990;862-867.
3. Brodowicz T., Wiltschke C., Kandioler-Eckersberger D.et al. Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids. Br. J. Cancer. 80:1999;1350-1358.
4. Tomazic V.J., Farha M., Loftus A., Elias E.G. Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro. J. Immunol. 140:1988;4056-4061.
5. Meager A. A cytotoxicity assay for tumour necrosis factor using a human rhabdomyosarcoma cell line. J. Immunol. Methods. 144:1991;141-143.
6. Schulze-Osthoff K., Bakker A.C., Vanhaesebroeck B., Beyaert R., Jacob W.A., Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J. Biol. Chem. 267:1992;5317-5323.
7. Claudio E., Segade F., Wrobel K., Ramos S., Bravo R., Lazo P.S. Molecular mechanisms of TNFalpha cytotoxicity. activation of NF-kappaB and nuclear translocation Exp. Cell Res. 224:1996;63-71.
8. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
9. Tartaglia L.A., Goeddel D.V. Two TNF receptors. Immunol Today. 13:1992;151-153.
10. Eggermont A.M., Schraffordt Koops H., Klausner J.M.et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann. Surg. 224:1996;756-764. (discussion 64-5.).
11. Eggermont A.M., Schraffordt Koops H., Lienard D.et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas. a multicenter trial J. Clin. Oncol. 14:1996;2653-2665.
12. Eggermont A.M., Schraffordt Koops H., Klausner J.M.et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas. Cancer Treat Res. 91:1997;189-203.
13. Gutman M., Inbar M., Lev-Shlush D.et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 79:1997;129-137.
14. Katsen A.D., Vollmar B., Mestres-Ventura P., Menger M.D. Cell surface and nuclear changes during TNF-alpha-induced apoptosis in WEHI 164 murine fibrosarcoma cells. A correlative light, scanning, and transmission electron microscopical study. Virchows Arch. 433:1998;75-83.
15. Lev-Chelouche D., Abu-Abeid S., Kollander Y.et al. Multifocal soft tissue sarcoma. limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan J. Surg. Oncol. 70:1999;185-189.
16. Ten Hagen T.L., Van Der Veen A.H., Nooijen P.T., Van Tiel S.T., Seynhaeve A.L., Eggermont A.M. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int. J. Cancer. 87:2000;829-837.
17. van Der Veen A.H., ten Hagen T.L., de Wilt J.H., van Ijken M.G., Eggermont A.M. An overview on the use of TNF-alpha. our experience with regional administration and developments towards new opportunities for systemic application Anticancer Res. 20(5B):2000;3467-3474.
18. Wiley S.R., Schooley K., Smolak P.J.et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1995;673-682.
19. Marsters S.A., Pitti R.M., Donahue C.J., Ruppert S., Bauer K.D., Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 6:1996;750-752.
20. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271:1996;12687-12690.
21. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59:1999;734-741.
22. Tanaka S., Sugimachi K., Shirabe K., Shimada M., Wands J.R. Expression and antitumor effects of TRAIL in human cholangiocarcinoma. Hepatology. 32:2000;523-527.
23. Ozawa F., Friess H., Kleeff J.et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 163:2001;71-81.
24. Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin. Cancer Res. 6:2000;4119-4127.
25. Van Valen F., Fulda S., Truckenbrod B.et al. Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int. J. Cancer. 88:2000;252-259.
26. Wu M., Das A., Tan Y., Zhu C., Cui T., Wong M.C. Induction of apoptosis in glioma cell lines by TRAIL/Apo-2l. J. Neurosci. Res. 61:2000;464-470.
27. Yamanaka T., Shiraki K., Sugimoto K.et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology. 32:2000;482-490.
28. Walczak H., Miller R.E., Ariail K.et al. Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo. Nat. Med. 5:1999;157-163.
29. Ashkenazi A., Pai R.C., Fong S.et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104:1999;155-162.
30. Pan G., O'Rourke K., Chinnaiyan A.M.et al. The receptor for the cytotoxic ligand TRAIL. Science. 276:1997;111-113.
31. Wu G.S., Burns T.F., McDonald E.R.et al. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene. 18:1999;6411-6418.
32. Wu G.S., Burns T.F., McDonald E.R.et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:1997;141-143.
33. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:1997;815-818.
34. Walczak H., Degli-Esposti M.A., Johnson R.S.et al. TRAIL-R2. a novel apoptosis-mediating receptor for TRAIL Embo J. 16:1997;5386-5397.
35. Screaton G.R., Mongkolsapaya J., Xu X.N., Cowper A.E., McMichael A.J., Bell J.I. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7:1997;693-696.
36. Sheridan J.P., Marsters S.A., Pitti R.M.et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:1997;818-821.
37. Degli-Esposti M.A., Smolak P.J., Walczak H.et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186:1997;1165-1170.
38. Pan G., Ni J., Yu G., Wei Y.F., Dixit V.M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 424:1998;41-45.
39. Marsters S.A., Sheridan J.P., Pitti R.M.et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7:1997;1003-1006.
40. Schneider P., Thome M., Burns K.et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 7:1997;831-836.
41. Kim K., Fisher M.J., Xu S.Q., el-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 6:2000;335-346.
42. Dejosez M., Ramp U., Mahotka C.et al. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ. 7:2000;1127-1136.
43. Ahmad M., Shi Y. TRAIL-induced apoptosis of thyroid cancer cells. potential for therapeutic intervention Oncogene. 19:2000;3363-3371.
44. Zhang X.D., Nguyen T., Thomas W.D., Sanders J.E., Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 482:2000;193-199.
45. Emery J.G., McDonnell P., Burke M.B.et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273:1998;14363-14367.
46. Keane M.M., Ettenberg S.A., Lowrey G.A., Russell E.K., Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56:1996;4791-4798.
47. Chou T.C., Talalay P. Analysis of combined drug effects. a new look at a very old problem Trends Pharmacol. Sci. 4:1983;450-454.
48. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships. the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22:1984;27-55.
49. Sacks P.G., Harris D., Chou T.C. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid. a rationale for combination therapy with chemotherapeutic agents Int. J. Cancer. 61:1995;409-415.
50. Grunt T.W. Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells. Cancer Lett. 189:2003;147-156.
51. Peter M.E. The trail discussion. it is FADD and caspase-8! Cell Death Differ. 7:2000;759-760.
52. Ogasawara J., Watanabe-Fukunaga R., Adachi M.et al. Lethal effect of the anti-Fas antibody in mice. Nature. 364:1993;806-809.
53. Brodowicz T., Kostler W.J., Wiltschke C., Zielinski C.C. Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide. Am. J. Clin. Oncol. 22:1999;535.
54. Verweij J., Lee S.M., Ruka W.et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults. a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group J. Clin. Oncol. 18:2000;2081-2086.
55. Kostler W.J., Brodowicz T., Attems Y.et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma. results of a phase II trial Ann. Oncol. 12:2001;1281-1288.